NO973635L - Fremgangsmåte for hemming av celle-celle adhesjon - Google Patents

Fremgangsmåte for hemming av celle-celle adhesjon

Info

Publication number
NO973635L
NO973635L NO973635A NO973635A NO973635L NO 973635 L NO973635 L NO 973635L NO 973635 A NO973635 A NO 973635A NO 973635 A NO973635 A NO 973635A NO 973635 L NO973635 L NO 973635L
Authority
NO
Norway
Prior art keywords
cell
inhibiting
cell adhesion
adhesion
inhibiting cell
Prior art date
Application number
NO973635A
Other languages
English (en)
Norwegian (no)
Other versions
NO973635D0 (no
Inventor
Brian William Grinnell
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO973635D0 publication Critical patent/NO973635D0/no
Publication of NO973635L publication Critical patent/NO973635L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO973635A 1995-02-09 1997-08-06 Fremgangsmåte for hemming av celle-celle adhesjon NO973635L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/385,934 US5484808A (en) 1995-02-09 1995-02-09 Methods of inhibiting cell-cell adhesion
PCT/US1996/002657 WO1996024384A1 (en) 1995-02-09 1996-02-09 Methods of inhibiting cell-cell adhesion

Publications (2)

Publication Number Publication Date
NO973635D0 NO973635D0 (no) 1997-08-06
NO973635L true NO973635L (no) 1997-09-29

Family

ID=23523494

Family Applications (1)

Application Number Title Priority Date Filing Date
NO973635A NO973635L (no) 1995-02-09 1997-08-06 Fremgangsmåte for hemming av celle-celle adhesjon

Country Status (17)

Country Link
US (2) US5484808A (uk)
EP (1) EP0726071A2 (uk)
JP (1) JPH10513475A (uk)
KR (1) KR19980702079A (uk)
CN (1) CN1072931C (uk)
AU (1) AU693021B2 (uk)
CA (1) CA2212339A1 (uk)
CZ (1) CZ286448B6 (uk)
HU (1) HUP9801323A3 (uk)
IL (1) IL117079A (uk)
MY (1) MY132251A (uk)
NO (1) NO973635L (uk)
NZ (1) NZ305072A (uk)
RU (1) RU2179021C2 (uk)
UA (1) UA43391C2 (uk)
WO (1) WO1996024384A1 (uk)
ZA (1) ZA961076B (uk)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US5770609A (en) 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6197789B1 (en) 1995-06-07 2001-03-06 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
US20030083733A1 (en) * 1997-10-10 2003-05-01 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6099562A (en) * 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US5837313A (en) * 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
US20020091433A1 (en) * 1995-04-19 2002-07-11 Ni Ding Drug release coated stent
US5747509A (en) * 1996-06-03 1998-05-05 Schering Aktiengesellschaft Method for lowering plasma levels of lipoprotein(a)
US5773432A (en) * 1996-10-30 1998-06-30 Schering Aktiengesellschaft Method for lowering plasma levels of lipoprotein(a)
WO1998046588A2 (en) * 1997-04-11 1998-10-22 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US6008232A (en) * 1997-08-20 1999-12-28 Eli Lilly And Company Methods for preventing headaches
AU3053199A (en) 1998-04-01 1999-10-25 Ono Pharmaceutical Co. Ltd. Fused thiophene derivatives and drugs containing the same as the active ingredient
ATE301129T1 (de) 1999-05-04 2005-08-15 Strakan Int Ltd Androgen glykoside und die androgenische aktivität davon
US6359015B1 (en) 2000-02-28 2002-03-19 The United States Of America As Represented By The Department Of Veterans Affairs Method for antagonizing inhibition effects of alcohol on cell adhesion
US7666588B2 (en) 2001-03-02 2010-02-23 Ibis Biosciences, Inc. Methods for rapid forensic analysis of mitochondrial DNA and characterization of mitochondrial DNA heteroplasmy
US20030027135A1 (en) * 2001-03-02 2003-02-06 Ecker David J. Method for rapid detection and identification of bioagents
US20040121309A1 (en) * 2002-12-06 2004-06-24 Ecker David J. Methods for rapid detection and identification of bioagents in blood, bodily fluids, and bodily tissues
US6613083B2 (en) * 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
JP3887588B2 (ja) * 2002-08-30 2007-02-28 株式会社リガク Ｘ線回折による応力測定法
US6977272B2 (en) * 2002-10-16 2005-12-20 President And Fellows Of Harvard College Method for antagonizing inhibition effects of alcohol on cell adhesion
EP1578399A4 (en) * 2002-12-06 2007-11-28 Isis Pharmaceuticals Inc METHODS FOR RAPID IDENTIFICATION OF PATHOGENS IN HUMANS AND BEETS
US7964343B2 (en) * 2003-05-13 2011-06-21 Ibis Biosciences, Inc. Method for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
US8097416B2 (en) 2003-09-11 2012-01-17 Ibis Biosciences, Inc. Methods for identification of sepsis-causing bacteria
US8546082B2 (en) 2003-09-11 2013-10-01 Ibis Biosciences, Inc. Methods for identification of sepsis-causing bacteria
US20120122101A1 (en) * 2003-09-11 2012-05-17 Rangarajan Sampath Compositions for use in identification of bacteria
US8163895B2 (en) 2003-12-05 2012-04-24 Ibis Biosciences, Inc. Compositions for use in identification of orthopoxviruses
US20050266411A1 (en) * 2004-05-25 2005-12-01 Hofstadler Steven A Methods for rapid forensic analysis of mitochondrial DNA
AU2006272776B2 (en) * 2005-07-21 2012-01-19 Ibis Biosciences, Inc. Methods for rapid identification and quantitation of nucleic acid variants
CN107412248A (zh) 2016-05-24 2017-12-01 中国医学科学院药物研究所 三乙酰基-3-羟基苯基腺苷在治疗血管炎症或改善血管内皮功能中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
US5356926A (en) * 1992-02-24 1994-10-18 Warner-Lambert Company 3-alkyloxy-, aryloxy-, or arylalkyloxy-benzo [β]thiophene-2-carboxamides as inhibitors of cell adhesion
TW383306B (en) * 1992-12-22 2000-03-01 Lilly Co Eli New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol
UA32427C2 (uk) * 1993-10-15 2000-12-15 Елі Ліллі Енд Компані Застосування бензотіофенів або їх фармацевтично прийнятних солей або сольватів для інгібування ангіогенезу і/або ангіогенних захворювань
US5457113A (en) * 1993-10-15 1995-10-10 Eli Lilly And Company Methods for inhibiting vascular smooth muscle cell proliferation and restinosis
US5441965A (en) * 1993-12-21 1995-08-15 Eli Lilly And Company Methods of inhibiting thrombin
US5574047A (en) * 1993-12-21 1996-11-12 Eli Lilly And Company Methods of inhibiting imperfect tissue repair
US5476862A (en) * 1993-12-21 1995-12-19 Eli Lilly And Company Methods of increasing thrombomodulin expression

Also Published As

Publication number Publication date
CN1173821A (zh) 1998-02-18
JPH10513475A (ja) 1998-12-22
IL117079A0 (en) 1996-06-18
MY132251A (en) 2007-09-28
AU693021B2 (en) 1998-06-18
EP0726071A3 (uk) 1996-09-11
UA43391C2 (uk) 2001-12-17
US5484808A (en) 1996-01-16
RU2179021C2 (ru) 2002-02-10
US5496851A (en) 1996-03-05
CN1072931C (zh) 2001-10-17
CZ248297A3 (cs) 1998-06-17
NO973635D0 (no) 1997-08-06
EP0726071A2 (en) 1996-08-14
CA2212339A1 (en) 1996-08-15
IL117079A (en) 1999-12-31
WO1996024384A1 (en) 1996-08-15
HUP9801323A3 (en) 1999-09-28
NZ305072A (en) 2000-07-28
CZ286448B6 (en) 2000-04-12
ZA961076B (en) 1997-08-11
AU5299696A (en) 1996-08-27
KR19980702079A (ko) 1998-07-15
HUP9801323A2 (hu) 1999-05-28
MX9706072A (es) 1997-10-31

Similar Documents

Publication Publication Date Title
NO973635L (no) Fremgangsmåte for hemming av celle-celle adhesjon
NO971520L (no) Fremgangsmåte for hemming av tilstander forbundet med neuropeptid Y
NO944911L (no) Ikke-peptid-takykininreseptorantagonister
NO944927L (no) Fremgangsmåte for inhibering av pulmonar hypertensiv sykdom
NO944919L (no) Fremgangsmåte for å inhibere atrofi av huden eller vagina
AU7578794A (en) Methods for inhibiting endometriosis
NO985864L (no) Nye anti-virale forbindelser
MX9701329A (es) Metodos para la inhibicion de la replicacion viral.
DK0659417T3 (da) Fremgangsmåder til inhibering af dysfunktionel blødning fra livmoderen
MX9701325A (es) Metodos para inhibir la mucositis ulcerativa.
MX9701360A (es) Metodos para la inhibicion de la desmielinizacion y las enfermedades de la dismielinizacion.
NO944926L (no) Fremgangsmåter for å inhibere myeloperoksidaseaktivitet
UA32427C2 (uk) Застосування бензотіофенів або їх фармацевтично прийнятних солей або сольватів для інгібування ангіогенезу і/або ангіогенних захворювань
NO944933L (no) Fremgangsmåte for å inhibere sykdomstilstander i brystet
EP0810221A4 (en) HETEROCYCLIC DERIVATIVES CONTAINING OXYGEN
NO944924L (no) Fremgangsmåter for inhibering av Turner's syndrom
NO970786L (no) Fremgangsmåte for hemming av benprotesedegradering
NO975580L (no) Fremgangsmåte for å inhibere melanom
NO944931L (no) Anvendelse av 2-fenyl-3-aroylbenzotiofener for inhibering av tidlig seksuell modenhet
NO981578L (no) FremgangsmÕte for hemming av plasminogenaktivatorhemmer I
NO973367L (no) Fremgangsmåte for å inhibere miljömessige östrogen
EA200000389A3 (ru) Новые замещенные пиридины или пиперидины, способ их получения и содержащие их фармацевтические композиции
NO973609L (no) Fremgangsmåte for å inhibere effektene av IL-6
NO971794L (no) Fremgangsmåte for hemming av tilstander forbundet med bradykinin
NO971029L (no) Fremgangsmåter for hemming av endometriale metoser

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application